CytomX Therapeutics Delivers Breakthroughs in Q4 2025 Results and Varseta Phase I Dose Expansion Data
CytomX Therapeutics has made significant strides in its Q4 2025 financial results and Varseta Phase I dose expansion data, marking a major milestone in the company's mission to revolutionize cancer treatment.
The recent conference call highlighted the impressive progress made by the EpCAM-targeting Probody antibody-drug conjugate Varseta-M in patients with late-line colorectal cancer. Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman, emphasized the importance of addressing the significant unmet need in oncology, citing that 1.9 million patients per year are diagnosed worldwide, a number predicted to grow to over 3 million by 2040.
Varseta-M is the first ADC (antibody-drug conjugate) for colorectal cancer, and its development has the potential to transform the treatment paradigm for this disease. The company highlighted that there are projected to be 45,000 addressable patients in the U.S. by 2040, creating a multibillion-dollar market opportunity.
Dr. Wayne Chu, CytomX's Chief Medical Officer, provided an update on the clinical data, noting the terrific progress made over the past 10 months. The company aims to develop Varseta-M aggressively for the benefit of patients with CRC and eventually other cancers.
The Phase I dose expansion data demonstrated a strong start in the clinical development of Varseta-M, with significant interest from the medical community since its first data disclosure in May last year. CytomX continues to be highly encouraged by what they've seen so far and are integrating all this data into future dose selection as they lock in on plans for late-stage development and registration.
In a stark contrast to the current standard of care, which offers objective response rates in the low single digits and progression-free survival of two to five months, Varseta-M is poised to bring significant improvements to patients with late-line metastatic CRC. As CytomX continues to push forward, it's clear that this breakthrough has the potential to change the game for cancer treatment.
